Trial Profile
Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2022
Price :
$35
*
At a glance
- Drugs Polidocanol (Primary)
- Indications Cancer metastases; Malignant melanoma
- Focus Therapeutic Use
- Acronyms INTRANS
- 12 Jul 2022 Planned End Date changed from 1 May 2022 to 1 Dec 2022.
- 12 Jul 2022 Planned primary completion date changed from 1 May 2022 to 1 Dec 2022.
- 12 Jul 2022 Status changed from recruiting to discontinued. Reason the study was stopped: Unable to identify eligible patients within planned timeframe